Anupam Rasayan India Ltd. has announced its entry into a definitive agreement to acquire a 43.3-48.2% equity stake in Bliss GVS Pharma Limited. The acquisition also includes an open offer to the public shareholders of Bliss GVS Pharma. This strategic move marks a significant step in Anupam Rasayan’s vision of building an integrated global life sciences and specialty pharmaceutical platform.
The total purchase consideration for the acquisition is being financed through a combination of a ₹300 crore term loan and a non-controlling, non-voting equity instrument for the balance amount. This acquisition is expected to strategically strengthen Anupam Rasayan’s presence across the pharmaceutical value chain, from key starting materials (KSMs) to finished dosage formulations.
Bliss GVS Pharma Limited, established in 1984, is an India-based pharmaceutical formulations company engaged in the development, manufacturing, marketing, and export of a wide range of dosage forms. The company is globally recognised for its leadership in suppositories and pessaries and operates multiple manufacturing facilities with approvals from US FDA, WHO-GMP, and EU-GMP.
Anupam Rasayan’s Managing Director, Anand Desai, commented on the acquisition, stating that it will unlock significant synergies through expanded product offerings, stronger regulated market presence, improved customer engagement, and accelerated innovation across regulated and semi-regulated markets. The acquisition is expected to enhance Anupam Rasayan’s global reach, especially in Europe and America, further strengthened by its recent acquisition of Jayhawk.
Anupam Rasayan India Ltd. is a prominent player in the custom synthesis and specialty chemicals sector in India, with a diverse customer base both domestically and internationally. The company operates eight manufacturing facilities and is involved in the production of life science-related specialty chemicals and other specialty chemicals.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).